CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Azacitidine (Vidaza) — Coverage Criteria

Defines medical coverage and authorization criteria for azacitidine (Vidaza) for FDA-approved and compendial hematologic malignancy indications for members of Neighborhood Health Plan of Rhode Island.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyAzacitidine (Vidaza) — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionRequest authorization for up to 12 months for listed indications and supply documentation showing no unacceptable toxicity or disease progression for reauthorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthstypical authorization period

FDA-approved + compendialcoverage stance

MDS, AML, JMML, BPDCNprimary conditions

Coverage and Medical Necessity Criteria

Initial therapy — covered indications

Covered when ALL of the following are met for listed indications

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Listed indication: Patient has an FDA‑approved indication (e.g., juvenile myelomonocytic leukemia [JMML]; adult myelodysplastic syndrome [MDS] subtypes including RA, RARS, RAEB, RAEB‑T, chronic myelomonocytic leukemia [CMML]) or a compendial use listed in the policy (e.g., acute myeloid leukemia [AML], accelerated phase or blast phase myelofibrosis, blastic plasmacytoid dendritic cell neoplasm [BPDCN], MDS/MPN overlap neoplasms)

See cited policy indications and compendial uses in source chunks 1, 2, and 8.

Authorization duration

Authorization limits and duration

Authorization period: Authorization may be granted for up to 12 months for covered indications12 months

Applies to MDS, AML, accelerated/blast phase myelofibrosis, BPDCN (including when combined with venetoclax for systemic palliative intent), and MDS/MPN overlap neoplasms as specified in the policy.

Continuation therapy

Reauthorization criteria

Reauthorization may be granted when there is no evidence of unacceptable toxicity or disease progression while on the current regimen

Authorization of up to 12 months may be granted for continued treatment for indications listed in the policy when these conditions are met.

Regimens and Drug Combinations

Regimen	Indication	Coverage status
Azacitidine (Vidaza) alone
For the treatment of relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Covered when used for relapsed or refractory BPDCN; authorization may be granted for up to 12 months
Azacitidine (Vidaza) in combination with venetoclax
For the treatment of systemic BPDCN with palliative intent
Covered when used in combination with venetoclax for systemic palliative intent; authorization may be granted for up to 12 months

Authorization, Documentation, and Provider Requirements

Prior Authorization

Continuation (Reauthorization) Requirements

Authorization of up to 12 months may be granted for continued treatment (reauthorization) for indications listed in this policy when the member is receiving therapy and the following continuation requirements are met: there is no evidence of unacceptable toxicity related to the therapy and there is no objective evidence of disease progression while on the current regimen.

Authorization period: up to 12 months for listed indications (e.g., MDS, AML, accelerated/blast phase myelofibrosis, BPDCN).
Reauthorization requirement: documentation in the medical record demonstrating lack of unacceptable toxicity AND no disease progression.
Acceptable documentation: clinical notes, labs, imaging, or treating oncologist attestation showing ongoing benefit and tolerability.

Documentation Required

Provider Documentation and Authorization Actions

Providers must confirm prior authorization is in place for initial and continued therapy per payer requirements and submit supporting clinical documentation at reauthorization. Lack of required documentation or evidence of disease progression or unacceptable toxicity may result in denial of continued coverage.

Ensure prior authorization request includes recent clinical assessment and objective measures of response or stability.
If toxicity is present, document management steps and rationale for continuing therapy (if applicable).
If disease progression is documented, include plan for alternative therapy or rationale for continued treatment.

Denial Risk

Non‑listed Indications

Therapies for indications not listed as FDA‑approved or compendial uses in this policy are considered experimental/investigational and are not eligible for coverage; reauthorization will not be granted for non‑covered indications.

Requests for indications outside the listed covered uses should be considered not medically necessary and will be denied.
Appeals may include peer‑reviewed literature supporting the off‑label use but do not guarantee coverage.

Clinical Definitions and Disease Categories

MDS/MPN overlap neoplasms — definition and policy notes

DefinitionMDS/MPN overlap neoplasms: myelodysplastic syndrome–myeloproliferative neoplasm overlap group including chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), atypical (BCR‑ABL–negative) chronic myeloid leukemia (aCML), MDS/MPN with neutrophilia, and unclassifiable MDS/MPN.

Examples listed in policyChronic myelomonocytic leukemia (CMML); juvenile myelomonocytic leukemia (JMML); atypical CML (aCML); MDS/MPN with neutrophilia; unclassifiable MDS/MPN.

Coverage stanceRecognized compendial indication for azacitidine (Vidaza) when criteria are met (covered with criteria).

Authorization noteAuthorization of up to 12 months may be granted for treatment of MDS/MPN overlap neoplasms when coverage criteria are satisfied.

ExclusionsAll other indications not listed in the policy are considered experimental/investigational and not medically necessary.

Background and Drug Information

Azacitidine (Vidaza) is indicated and used in the treatment of a range of myeloid neoplasms. Compendial uses cited in this policy include treatment of accelerated phase or blast phase myelofibrosis, acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap neoplasms. Uses not listed in the compendial or FDA‑approved sections are considered investigational and not medically necessary.